Stock Market News

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

wcc wcc
Mar 06, 2026 - 15:50
0 1
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
Previous Article

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to...

Next Article

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 fr...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0
wcc
wcc

Related Posts

BitGo Cuts 15% of Workforce to Focus on Stablecoins and AI

BitGo Cuts 15% of Workforce to Focus on Stablecoins ...

wcc
Jun 27, 2026
0
0
Nebius Group N.V. (NBIS): 10 Stocks That Could Double Over the Next 2 Years

Nebius Group N.V. (NBIS): 10 Stocks That Could Doubl...

wcc
Jun 27, 2026
0
0

SpaceX will join Nasdaq-100

wcc
Jun 27, 2026
0
0

From concerts to train rides, bots are winning the t...

wcc
Jun 27, 2026
0
0
Best AI ETFs Compared: CHAT vs BOTZ vs AIS (2026)

Best AI ETFs Compared: CHAT vs BOTZ vs AIS (2026)

wcc
Jun 27, 2026
0
0
Here is why Westlake Corporation (WLK) is among the 10 Most Promising Hydrogen and Fuel Cell Stocks According to Analysts

Here is why Westlake Corporation (WLK) is among the ...

wcc
Jun 27, 2026
0
0

Comments (0)

User